A “minimalist” approach to transfemoral valve-in-valve transcatheter mitral valve replacement (TMVR), not unlike the approach commonly used with TAVI, appears to be safe and feasible when compared ...
The global Transcatheter Mitral Valve Replacement (TMVR) market is witnessing rapid expansion and is expected to grow at a strong CAGR of nearly 20% during the forecast period. The increasing burden ...
An estimated 50,000 people in the United States undergo open-heart surgery each year for the treatment of a leaking mitral valve. However, this major surgery is not an option when patients are too old ...
DUBLIN, Feb. 12, 2021 /PRNewswire/ -- The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering. Transcatheter treatment includes ...
Cardiac surgeons Dr. Talwinderdeep Kahlon, left, and Dr. James MacMillian, right, at Doctors Medical Center in Modesto in Modesto, Calif., Wednesday, Dec. 19, 2018. The hospital is now offering ...
NEW YORK CITY -- Mitral valve technology developers were urged to go back to the drawing board due to current-generation devices not meeting the needs of enough patients with mitral regurgitation (MR) ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...
DENVER, CO — Two cardiac valve prostheses, similar in capability, offer the prospect of significant relief of mitral regurgitation (MR) via transcatheter mitral-valve replacement (TMVR) for patients ...
MedPage Today on MSN
AltaValve System Shows Promise for Severe Mitral Regurgitation in 1-Year Results
LVOT-sparing device designed for broader applicability of transcatheter mitral valve repla ...
Abbott Laboratories has received approval for a mitral valve replacement that can be implanted without open-heart surgery. The U.S. Food & Drug Administration gave the OK for the North Chicago-based ...
LivaNova announced plans to restructure its heart valve operations, and that it will drop its investigational Caisson transcatheter mitral valve replacement program altogether. Though its valve ...
TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results